Results 91 to 100 of about 29,286 (231)

Dasatinib-induced nephrotic syndrome in a patient with chronic myelogenous leukemia: a case report

BMC Nephrology, 2019
Background Dasatinib is a second-generation tyrosine kinase inhibitor that is indicated for the treatment of patients with chronic myeloid leukemia. Here, we report the case of a man with nephrotic syndrome that was caused by dasatinib. Case presentation
Shoko Ochiai, Yuji Sato, Akihiro Minakawa, Akihiro Fukuda, Shouichi Fujimoto   +4 more
doaj   +1 more source

Electromechanical modelling and simulation of human‐induced pluripotent stem cell‐derived cardiomyocytes predict drug‐induced contractility effects

The Journal of Physiology, EarlyView.
Abstract figure legend A study described in this paper describes a new tool for hiPSC‐CM electromechanical behaviour simulations using mathematical modelling. The model enables in silico assays making drug testing quick, comprehensive and accurate. New hiPSC‐CM models can be used as a platform to integrate in vitro and in silico findings.
Milda Folkmanaite, Xin Zhou, Andreas Koschinski, Wan‐Hua Hong, Marilù Casini, Manuel Koch, Ursula Ravens, Remi Peyronnet, Manuela Zaccolo, Blanca Rodriguez   +9 more
wiley   +1 more source

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia

, 2009
Radhakrishnan Ramchandren, Charles A SchifferDivision of Hematology/Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USAAbstract: The development of imatinib for the treatment of chronic myeloid leukemia (CML ...
Radhakrishnan Ramchandren, Charles A Schiffer   +1 more
core  

Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation [PDF]

, 2017
Tyrosine kinase inhibitors (TKI) improve the prognosis of patients with chronic myelogenous leukemia (CML) by inducing substantial deep molecular responses (DMR); some patients have successfully discontinued TKI therapy after maintaining DMR for ≥1 year.
Nakaseko, Chiaki, Sakamaki, Hisashi, Kumagai, Takashi, Kouzai, Yasuji, Matsue, Kosei, Takano, Hina, Tadashi Murase, Kaichi Nishiwaki, Wakita, Hisashi, Nishiwaki, Kaichi, Hisashi Sakamaki, Junichi Sakamoto, Satoshi Morita, Takezako, Naoki, Hina Takano, Kazuteru Ohashi, Koiti Inokuchi, Chikashi Yoshida, Yoshida, Chikashi, Murase, Tadashi, Morita, Satoshi, Takashi Kumagai, Hisashi Wakita, Inokuchi, Koiti, null null, Sakamoto, Junichi, Chiaki Nakaseko, Kosei Matsue, Ohashi, Kazuteru, Naoki Takezako, Yasuji Kouzai, the Kanto CML and Shimousa Hematology Study Groups   +31 more
core   +1 more source

Born early, age fast: Consequences of premature birth on chronic disease and accelerated ageing

The Journal of Physiology, EarlyView.
Abstract figure legend ELGANs are exposed to several postnatal pro‐oxidant stressors, including ambient and supplemental oxygen, mechanical ventilation, infections, hyperalimentation, excessive glucocorticoids and intermittent hypoxia. Since endogenous antioxidant defences are underdeveloped, this imbalance promotes oxidative stress and inflammation ...
Estelle B. Gauda, Julijana Ivanovska, Dwayne Mascarenhas, Jeffrey Antwi, Atefeh Mohammadi, Bonny Jasani   +5 more
wiley   +1 more source

First-line therapy of chronic myeloid leukemia – focus on dasatinib

Blood and Lymphatic Cancer: Targets and Therapy, 2012
Philip C AmreinHematology-Oncology, Massachusetts General Hospital, Boston, USAAbstract: Dasatinib is a broad spectrum, ATP-competitive, tyrosine kinase inhibitor with low nM activity against Bcr-Abl, Src, and other tyrosine kinases.
Amrein PC
doaj  

Beat‐to‐beat variability of ventricular repolarization reveals sex‐specific instability and proarrhythmic risk

The Journal of Physiology, EarlyView.
Abstract figure legend A mechanistic framework linking sex‐dependent dynamical instability to proarrhythmic risk. Sex‐specific human ventricular models show that upstream modulators, including biological sex, hormones, drugs and heart disease, promote steeper APD restitution in female than male and enhance dynamical instability.
Daisuke Sato, Lorenzo Santini, Raffaele Coppini, Eleonora Grandi   +3 more
wiley   +1 more source

The role of dasatinib in the management of chronic myeloid leukemia

, 2015
Runzhe Chen, Baoan Chen Department of Hematology and Oncology (Key Department of Jiangsu Medicine), Zhongda Hospital, Medical School, Southeast University, Nanjing, Jiangsu Province, People’s Republic of China Abstract: Dasatinib is a second-
Chen R, Chen B
core  

Delayed Gastric Bleeding in a Patient With Chronic Myeloid Leukemia: A Case of Post‐Biopsy Bleeding

DEN Open, Volume 7, Issue 1, April 2027.
The presence of underlying conditions, particularly malignancies such as myeloproliferative disorders, may increase the risk of delayed bleeding following gastric mucosal biopsy, and similar cases warrant careful accumulation and evaluation in future. ABSTRACT A 76‐year‐old man was referred to our hospital for evaluation of anemia.
Yoko Kosaka, Hiromichi Yamane, Hidekazu Nakanishi, Nagio Takigawa   +3 more
wiley   +1 more source

A physiologically‐based pharmacokinetic precision dosing approach to manage dasatinib drug–drug interactions

CPT: Pharmacometrics & Systems Pharmacology
Dasatinib, a second‐generation tyrosine kinase inhibitor, is approved for treating chronic myeloid and acute lymphoblastic leukemia. As a sensitive cytochrome P450 (CYP) 3A4 substrate and weak base with strong pH‐sensitive solubility, dasatinib is ...
Christina Kovar, Helena Leonie Hanae Loer, Simeon Rüdesheim, Laura Maria Fuhr, Fatima Zahra Marok, Dominik Selzer, Matthias Schwab, Thorsten Lehr   +7 more
doaj   +1 more source